Ontology highlight
ABSTRACT: Importance
Myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) are consistently identified in a range of demyelinating disorders in adults and children. Current therapeutic strategies are largely center specific, and no treatments have been formally evaluated.Objective
To examine the clinical phenotypes, treatment responses, and outcomes of children with relapsing MOG-Ab-associated disease.Design, setting, and participants
This study prospectively collected demographic, clinical, and radiologic data from 102 patients from 8 countries of the EU Paediatric Demyelinating Disease Consortium from January 1, 2014, through December 31, 2016. Patients were treated according to local protocols.Main outcomes and measures
Annualized relapse rates (ARRs) and Expanded Disability Status Scale (EDSS) scores before and during treatment with disease-modifying drugs (DMDs).Results
A total of 102 children were identified (median [range] age, 7.0 [1.5-7.9] years; male to female ratio, 1.0:1.8; white to other race/ethnicity ratio, 3.6:1.0). Original diagnoses were neuromyelitis optica spectrum disorder (44 patients [43.1%]), acute disseminated encephalomyelitis followed by optic neuritis (20 [19.6%]), multiphasic disseminated encephalomyelitis (20 [19.6%]), and relapsing optic neuritis (18 [17.6%]). In all, 464 demyelinating events were reported. Treated patients had more relapses (median, 3.0; range, 1.0-17.0) than untreated patients (median, 1.0; range 1.0-7.0) (P?=?.009) and higher EDSS scores (median, 1.5; interquartile range, 0-2.5) than untreated patients (median, 1.0; interquartile range, 0-1.5) (P?Conclusions and relevanceAlthough commonly used to treat patients with multiple sclerosis, DMDs were not associated with clinical improvement in children with MOG-Ab-associated disease, whereas azathioprine, mycophenolate mofetil, rituximab, and particularly intravenous immunoglobulins were associated with a reduction in relapse frequency. A correct diagnosis of relapsing MOG-Ab-associated disorders is therefore important to optimize immune treatment.
SUBMITTER: Hacohen Y
PROVIDER: S-EPMC5885190 | biostudies-literature | 2018 Apr
REPOSITORIES: biostudies-literature
Hacohen Yael Y Wong Yu Yi YY Lechner Christian C Jurynczyk Maciej M Wright Sukhvir S Konuskan Bahadir B Kalser Judith J Poulat Anne Lise AL Maurey Helene H Ganelin-Cohen Esther E Wassmer Evangeline E Hemingway Chery C Forsyth Rob R Hennes Eva Maria EM Leite M Isabel MI Ciccarelli Olga O Anlar Banu B Hintzen Rogier R Marignier Romain R Palace Jacqueline J Baumann Matthias M Rostásy Kevin K Neuteboom Rinze R Deiva Kumaran K Lim Ming M
JAMA neurology 20180401 4
<h4>Importance</h4>Myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) are consistently identified in a range of demyelinating disorders in adults and children. Current therapeutic strategies are largely center specific, and no treatments have been formally evaluated.<h4>Objective</h4>To examine the clinical phenotypes, treatment responses, and outcomes of children with relapsing MOG-Ab-associated disease.<h4>Design, setting, and participants</h4>This study prospectively collected demograph ...[more]